Investors & Media

What’s new.

Press releases

Press releases.

April 2nd 2025

Immutep to Participate in Upcoming Investor Conferences

March 25th 2025

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

March 20th 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

more

Investor updates

Investor updates.

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

more

Analyst reports

Analyst reports.

March 25th 2025

Maxim - P3 Study for Efti + Keytruda in 1L NSCLC Doses First Patient - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

March 25th 2025

Baird - First Patient Dosed in Phase 3 TACTI-004 for Efti Combo in 1L NSCLC; Rated OP, US$7 PT (Analyst: Colleen Kusy)

For a copy of this research report please contact your Baird advisor

March 4th 2025

Canaccord Genuity - 1H25 model update: All eyes on next HNSCC update; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

more